sumi.news
Search
Following
Sign in
← Back to news
Y
Yahoo Finance
RSS Feed
finance.yahoo.com
finance.yahoo.com/rss
Follow
Latest
Sun May 3
TD Securities Remains Bullish on Royal Bank of Canada (RY)
1d
Y
CIBC Lifts PT on The Toronto-Dominion Bank (TD)
1d
Y
Wall Street Is Ignoring This Beaten-Down Value Stock Under $10
1d
Y
Gilead Sciences (GILD) Announces New Results From a Post Hoc Analysis
1d
Y
This SpaceX-Linked Chip Stock Is Surging. Data Center Revenue Could Double in 2027.
1d
Y
Merck & Co. (MRK) Announces Quarterly Dividend
1d
Y
Mastercard names Ling Hai CFO, moves Sachin Mehra to new role
1d
Y
Here’s What Analysts Are Saying About Salesforce (CRM)
1d
Y
Is Sandisk Corporation (SNDK) One of the Best Inexpensive Stocks to Invest in Right Now?
1d
Y
Is The Walt Disney Company (DIS) One of the Best Inexpensive Stocks to Invest in Right Now?
1d
Y
Is Micron Technology (MU) One of the Best Inexpensive Stocks to Invest in Right Now?
1d
Y
Dollar General Beats Earnings Estimates. The Stock Is Falling Anyway.
1d
Y
Chief Risk Officer Sells 11,250 Shares of Regional Insurer, According to Latest SEC Filing
1d
Y
Abivax stock plunges on cancer signal in ulcerative colitis trial
1d
Y
Is Pfizer Inc. (PFE) Expanding Its Cancer Pipeline Through a Landmark Innovent Partnership?
1d
Y
Gilead Sciences, Inc. (GILD) Gains Attention as Livdelzi Demonstrates Long-Term Efficacy and Safety
1d
Y
GSK plc (GSK) Launches Ask2BSure Meningitis Awareness Campaign With Celebrity Advocates
1d
Y
Why Zoetis Inc. (ZTS) Was Downgraded Following Steep Market Selloff?
1d
Y
Why Canaccord Reduced Prestige Consumer Healthcare Inc. (PBH) Price Target After Q4 Weakness
1d
Y
Amphastar Pharmaceuticals, Inc. (AMPH) Price Target Cut to $21 At Piper Sandler Amid Pipeline Uncertainty
1d
Y
Grifols, S.A. (GRFS) Sees Strong Biopharma Growth Led by Gamunex and Yimmugo
1d
Y
Dell Stock Is the New Nvidia of AI Infrastructure
1d
Y
Franklin Templeton Taps MoonPay to Bring Stablecoin Cash Into Tokenized Funds
1d
Y
Victoria’s Secret Stock Surges 48% After Earnings. What’s Driving the Gains.
1d
Y
The SpaceX IPO Is Whipping Space Stocks Into a Frenzy
1d
Y
Stocks Pressured by Uncertainty of US-Iran Ceasefire Prospects
1d
Y
Signet Jewelers Q1 Earnings Call Highlights
1d
Y
Absa gets approval to buy Standard Chartered Uganda assets
1d
Y
The record-setting S&P 500 is putting up some impressive stats: By the numbers
1d
Y
Salesforce (CRM) Shows Narrative Divergence Amid Anthropic’s Developments
1d
Y
Tech Tuesday: Coppel Teams with First Insight
1d
Y
Netflix Nearing 52-Week Low: Buy, Sell or Hold?
1d
Y
KB (KB) Q1 2026 Earnings Call Transcript
1d
Y
Is Ironwood Pharmaceuticals, Inc. (IRWD) Strengthening Its Growth Outlook With Expanded Pediatric Approval for Linzess?
1d
Y
Why HUTCHMED (China) Limited (HCM) Is Gaining Attention After China Biotech Re-Rating
1d
Y
Evaluating Zoom’s (ZM) Event-Driven Trade
1d
Y
Is Fold Holdings, Inc. (FLD) Under Pressure After Revenue Drops 21% in Q1 2026?
1d
Y
Is FibroBiologics, Inc. (FBLG) Advancing Toward a Breakthrough Psoriasis Treatment With CYPS317 Data?
1d
Y
TScan Therapeutics, Inc. (TCRX) Reports Q1 2026 Results With Improved Net Loss
1d
Y
Why Lucid Diagnostics Inc. (LUCD) Faced a Price Target Reduction After Q1 Results
1d
Y
Is Expensify, Inc. (EXFY) Strengthening Its Expense Ecosystem Through New VAT Reclaim Partnership?
1d
Y
Covenant (CVLG) Q1 2026 Earnings Transcript
1d
Y
GoPro, Inc. (GPRO) Stock Focus Shifts to Diversification Beyond Action Cameras
1d
Y
Target vs Walmart: Both Fighting For The Same Customer, Only One Wins
1d
Y
Business Owners: The One Tax Move Financial Advisors Say You Can’t Skip Before Year-End
1d
Y
Why PMV Pharmaceuticals, Inc. (PMVP) Faces Funding Concerns Despite Positive Trial Activity
1d
Y
Is Cognition Therapeutics, Inc. (CGTX) Moving Closer to a Registrational Trial in Dementia With Lewy Bodies?
1d
Y
Is ESS Tech, Inc. (GWH) Still a Buy After Softer Q1 Results and Lower Price Target?
1d
Y
Is Kymera Therapeutics, Inc. (KYMR) a Long-Term Biotech Winner After New Buy Rating and Coverage Launch At Canaccord?
1d
Y
MoonLake Immunotherapeutics (MLTX) Price Target Raised to $45 At H.C. Wainwright on FDA Progress
1d
Y
More →